SCHEMBL2820127

SCHEMBL2820127

O=[N+]([O-])c1ccc(Oc2cccc(Cl)c2Cl)c(S(=O)(=O)N2CCNCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TBXA2R P21731 2/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
NPSR1 Q6W5P4 2/20 0.43
HPGD P15428 1/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
POLB P06746 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
MAPK1 P28482 2/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
CYP2C19 P33261 1/20 0.42
TP53 P04637 1/20 0.42
CYP2D6 P10635 1/20 0.42
NFKB1 P19838 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2820557 0.92 TBXA2R (0.53) ALDH1A1KMT2AMEN1SMN1; SMN2TBXA2R
SCHEMBL2818936 0.88 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1SMN1; SMN2L3MBTL1
SCHEMBL3112601 0.84 TBXA2R (0.54) ALDH1A1KMT2AMEN1SMN1; SMN2TBXA2R
SCHEMBL2823731 0.84 KMT2A (0.43) ALDH1A1KMT2AMEN1SMN1; SMN2TBXA2R
SCHEMBL2819545 0.84 L3MBTL1 (0.54) ALDH1A1KMT2AMEN1SMN1; SMN2TBXA2R
SCHEMBL2820494 0.84 HSPB1 (0.54) ALDH1A1KMT2AMEN1SMN1; SMN2TBXA2R
SCHEMBL2820383 0.84 KMT2A (0.55) ALDH1A1KMT2AMEN1SMN1; SMN2TBXA2R
SCHEMBL2821044 0.84 TBXA2R (0.53) ALDH1A1KMT2AMEN1SMN1; SMN2TBXA2R
SCHEMBL693154 0.84 USP2 (0.54) ALDH1A1KMT2AMEN1SMN1; SMN2L3MBTL1
SCHEMBL2820559 0.84 KMT2A (0.48) ALDH1A1KMT2AMEN1SMN1; SMN2TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1849469-B1 Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS INC (US) 2010-10-27 EP claimed
US-7700586-B2 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS, INC. (US) 2010-04-20 US claimed
US-8242118-B2 Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS INC. (US) 2012-08-14 US disclosed
US-20100204213-A1 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS BAYER HEALTHCARE AG (DE) 2010-08-12 US disclosed
US-7700586-B2 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS, INC. (US) 2010-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204213-A1 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS CCR3, CCR1, CCR2 ALDH1A1 2416/4885KMT2A 2753/4885MEN1 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.